<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Physicians face a therapeutic dilemma in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> hemorrhagic <z:hpo ids='HP_0001297'>stroke</z:hpo> requiring long-term, high-intensity <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> because this treatment increases the risk of <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>) 8- to 11-fold </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively studied 15 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> which occurred under anticoagulation with <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi>, with an international norrmalized ratio (INR) of 2.5-6.5 on admission </plain></SENT>
<SENT sid="2" pm="."><plain>Hemispheric, thalamic, cerebellar, intraventricular, or <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> without <z:hpo ids='HP_0002617'>aneurysm</z:hpo> occurred </plain></SENT>
<SENT sid="3" pm="."><plain>Absolute indications for anticoagulation were double, mitral, or aortic valve replacement, combined <z:e sem="disease" ids="C0865577" disease_type="Disease or Syndrome" abbrv="">mitral valve failure</z:e> with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and atrial enlargement, internal carotid artery-jugular vein graft, frequently recurring <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> with risk of <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>, and severe nontreatable <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>As soon as the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> was established, INR normalization was attempted in <z:hpo ids='HP_0000001'>all</z:hpo> patients by administration of prothrombin complex, fresh frozen plasma, or <z:chebi fb="6" ids="28384">vitamin K</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>After giving <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> (and neurosurgical therapy in four patients) <z:chebi fb="5" ids="28304">heparin</z:chebi> administration was started </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients received full-dose intravenous and six low-dose subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The following observations were made: (a) <z:hpo ids='HP_0000001'>All</z:hpo> patients with effective, full-dose <z:chebi fb="5" ids="28304">heparin</z:chebi> treatment with a 1.5- to 2-fold elevation in partial thromboplastin time after normalization of the INR were discharged without complication </plain></SENT>
<SENT sid="8" pm="."><plain>(b) Three of four of the patients with only incomplete correction of the INR (&gt; 1.35) experienced relevant rebleeding within 3 days (<z:hpo ids='HP_0000001'>all</z:hpo> patients with an INR higher than 1.5), two of whom were on full-dose <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>(c) Three of seven of the patients with normalized INR and without significant PTT elevation developed severe <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Although our data are based on a retrospective analysis, they support treatment with intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> (partial thromboplastin time 1.5-2 times baseline value) after normalization of the INR in patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> and an urgent need for anticoagulation </plain></SENT>
</text></document>